The EMPAG-HF (12), Ibrahim (15), and López-Vilella 2022 (18) trials demonstrated a significant difference in diuretic efficiency between the SGLT2 inhibitors and placebo groups (P < 0.05). This evidence concerns the gene SLC5A2 and hydrops fetalis.